|
Diagnosis and Evidence-Based Management of T-Cell Lymphoma
STATEMENT OF NEED
T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging (Salem et al, 2021). In this webinar, Aaron Goodman, MD, will update clinic... |
|
|
Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis
Learn more about myelofibrosis risk factors, novel therapies to slow disease progression and reduce symptoms, and strategies to maintain quality of life in this comprehensive activity presented by John Mascarenhas, MD, Professor of Medicine at Mount Sinai Icahn School of Medicine. Start the activity now!
STATEMENT OF NEED
Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bon... |
|
|
Key Considerations in Managing Atopic Dermatitis in Black Patients
Statement of Need
Atopic dermatitis (AD), a severe form of eczema and intense pruritus, is associated with a substantial and multifaceted patient-reported burden that encompasses sleep disturbances, anxiety, depression, reduced function/productivity, and impaired quality of life. The incidence of AD is high, estimated to be approximately 15%-20% in children and 1%-3% in adults worldwide (Yong & Tay, 2017). Population studies within the United States have shown that AD disproportionately... |
|
|
Podcast: Key Considerations in Managing Atopic Dermatitis in Black Patients
Statement of Need
Atopic dermatitis (AD), a severe form of eczema and intense pruritus, is associated with a substantial and multifaceted patient-reported burden that encompasses sleep disturbances, anxiety, depression, reduced function/productivity, and impaired quality of life. The incidence of AD is high, estimated to be approximately 15%-20% in children and 1%-3% in adults worldwide (Yong & Tay, 2017). Population studies within the United States have shown that AD disproportionately... |
|
An Illustrated Guide to Meeting the Challenges of Treating Hemophilia
In this activity, Steven Pipe, MD and Guy Young, MD introduce the unmet medical needs experienced by patients with hemophilia. They review the mechanisms of action and most recent clinical trial data for the most advanced substitution therapies (emicizumab), hemostatic rebalancing agents (concizumab, marstacimab, and fitusiran), and gene therapies. The faculty also discuss how approval of these treatments could affect patient care, and the questions that need to be addressed in ongoing phase 3... |
|
|
New Perspectives in the Management of Marginal Zone Lymphoma
STATEMENT OF NEED
Marginal zone lymphoma (MZL) comprises approximately 7% of all mature non-Hodgkin lymphomas (NHLs) (Cerhan & Haberman, 2021). According to the World Health Organization classification, there are three subtypes: extranodal MZL, also referred to as mucosa-associated lymphatic tissue (MALT) lymphoma; splenic MZL, which originates from memory B lymphocytes located in the marginal zone of secondary lymphoid follicles present in the spleen; and nodal MZL, which originates in... |
|
|
New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease
STATEMENT OF NEED
Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the first year following HSCT but may develop in subsequent years. It most commonly affects the skin; howe... |
|
|
Podcast: New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease
STATEMENT OF NEED
Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the first year following HSCT but may develop in subsequent years. It most commonly affects the skin; howe... |
|
|
Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy
CIPN is a complication of cancer treatment that may lead to permanent nerve damage in severe cases. This online activity reviews causative agents, signs and symptoms, and supportive care interventions.
1.0 NCPD | ILNA
STATEMENT OF NEED
Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to treatment dose reductions or discontinuation in severe cases. In one study of 123 patients receiving taxane therapy for bre... |
|
|
Overcoming Nursing Management Challenges in Metastatic Castration-Resistant Prostate Cancer
STATEMENT OF NEED
Prostate cancer is the most common tumor type affecting men in the United States. An estimated 268,490 new cases are diagnosed annually, and 34,500 people die of the disease (ACS, 2022). Typically, androgen deprivation therapy (ADT) is administered for progressive disease. However, castration resistance or unresponsiveness to ADT or antiandrogens frequently develop over time. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease proces... |
|
|
Podcast: Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer
This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Start the activity now.
Statement of Need
An ... |
|
|
Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer
This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Start the activity now.
Statement of Need
An ... |
|
|
Novel Breast Cancer Therapies: Antibody-Drug Conjugates
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with an estimated 15% of cases being human epidermal growth factor receptor 2 (HER2)"positive and 12% being triple-negative (ACS, 2019). Antibody-drug conjugates have revolutionized the treatment of HER2-positive, triple-negative, and, most recently, HER2-low unresectable or metastatic breast cancer. These drugs combine a tumor antigen"targeted monoclonal antibody with a cytotoxic payload to permit the s... |
|
|
Novel Breast Cancer Therapies: Immune Checkpoint Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is
estimated that 12% of cases are classified as triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) (ACS, 2019). Immune checkpoint inhibition in combination with chemotherapy is a new strategy in breast cancer, with the first immunotherapy approval for patients with advanced triple-negative disease occurring in 2019. Immune checkpoint inhibit... |
|
|
Novel Breast Cancer Therapies: CDK4/6 Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with 287,850 new cases and 43,250 deaths predicted to occur in 2022 (ACS, 2022). Making up 73% of cases, hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative disease is the most common subtype of breast cancer (ACS, 2019). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a novel therapeutic option for patients with HR-positive, HER2-negative advanced breast cancer. T... |
|
|
Novel Breast Cancer Therapies: HER2 Tyrosine Kinase Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are HER2-positive and may therefore benefit from human epidermal growth factor receptor 2 (HER2) inhibition (ACS, 2019). By blocking downstream oncogenic signaling in HER2-positive breast cancer cells, HER2 tyrosine kinase inhibitors improve outcomes for patients with HER2-positive breast cancer. These agents have advantages over monoclonal antibody HER2 inhibitors because the... |
|
|
Novel Breast Cancer Therapies: Monoclonal Antibodies
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are human epidermal growth factor receptor 2 (HER2)"positive and may therefore benefit from HER2 inhibition (ACS, 2019). Monoclonal antibodies target HER2 function by preventing the formation or blocking the signaling of the oncogene HER2. The resulting loss of signaling downregulates oncogenic signaling in the cancer cell, resulting in improved clinical outcomes for pati... |
|
|
Novel Breast Cancer Therapies: PARP Inhibitors
STATEMENT OF NEED
Breast cancer is the most commonly diagnosed cancer in women. A BRCA1 or BRCA2 mutation is found in approximately 5% of patients with breast cancer and is detected in 30% of patients who have a family history of breast or ovarian cancer (ACS, 2019). In patients with human epidermal growth factor receptor 2 (HER2)"negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, inhibition of poly"(ADP-ribose) polymerase (PARP) is highly ef... |
|
|
Novel Breast Cancer Therapies: PI3K Inhibitors
STATEMENT OF NEED
Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019). In breast cancer, phosphatidylinositol-3-kinase (PI3K) overactivation is often associated with an activating mutation in the catalytic alpha subunit of PI3K (PIK3CA). These activating mutations occur in more than one third of breast cancers... |
|
|
Evolving Treatment Concepts and New Data in Advanced Prostate Cancer
STATEMENT OF NEED
Prostate cancer is the most common tumor type affecting men in the United States. It is estimated that 268,490 new cases were diagnosed and that 34,500 people died of prostate cancer in 2022 (Siegel et al, 2022). Prostate cancer alone accounts for 27% of all cancer diagnoses in men (ACS, 2022). To optimize outcomes for patients with prostate cancer, it is critical for health care providers to be familiar with the most recent evidence on therapy selection, biomarker testing... |
|
|
Cracking the Code for Improved Patient Outcomes in Advanced Renal Cell Carcinoma
STATEMENT OF NEED
Renal cell carcinoma (RCC) comprises 2.4% of malignancies in adults worldwide (Makino et al, 2022). It is estimated that 79,000 new cases of kidney cancer were diagnosed in the US in 2022 (Siegel et al, 2022). RCC is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Several new therapies have been approved for RCC in recent years; therefore, it is important for the cancer care team to update their... |
|
|
Oncology Data Advisor™: Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians need to continually update their working knowledge of emerging data and consensus recommendations that can rationally inform clinical decision making. In Modul... |
|
|
Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Cancers
STATEMENT OF NEED
Esophagogastric cancers include tumors of the esophagus, esophageal junction, and stomach. Esophageal cancers are the twentieth most commonly diagnosed cancer in the United States, but the eleventh leading cause of cancer death, with an estimated 21,560 cases diagnosed annually and 16,120 deaths estimated in 2023 (NCCN, 2023; Siegel et al, 2023). Given the poor prognosis of esophagogastric cancers and the complexity of personalized care planning, interdisciplinary teamwork... |
|
|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Management of Large B-Cell Lymphomas: A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-Cell Therapy
TARGET AUDIENCE:
Hematologist-oncologists, pathologists, histologists, advanced practitioners, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients diagnosed with LBCL.
PROGRAM OVERVIEW:
In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive c... |
|
|
Identification of Relapsed ALL
Target Audience
The target audience for this initiative includes hematology/oncology physicians and other members of the multidisciplinary cancer care team involved in the management of patients with acute lymphocytic leukemia.
Program Overview
This activity is the first in a series of four modules on relapsed/refractory acute lymphocytic leukemia (ALL). Module 1 focuses on identification of relapsed ALL. This education is presented by Dr. Reshma Ramlal from the University of Kentucky Mar... |
|
|
Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago Race, Ethnicity, and Breast Cancer: Screening and Diagnosis
This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women treated in Cook County.
In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses screening and mammography rates am... |
|
|
Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago Race, Ethnicity, and Breast Cancer: Treatment
This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women treated in Cook County.
In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses the oncology, surgical, and radiat... |
|
|
Expert Insights: Precision Medicine in Non-Small Cell Lung Cancer
TARGET AUDIENCE:
This activity is designed to meet the educational needs of advanced practitioners (NP/PA), and other healthcare professionals involved in the care of patients with NSCLC.
PROGRAM OVERVIEW:
This activity will cover Non-Small Cell Lung Cancer.
LEARNING OBJECTIVES:
Upon completion of this activity, participants should be better able to:
• Assess current biomarker testing guidelines for patients with NSCLC, including recommended strategies to detect common driver mutatio... |
|
|
Internal Medicine Comprehensive Review and Update 2023 - LIVE STREAMING
Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties
This program, the 63rd Annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care.
This program covers the breadth of Internal Medicine subspecialties, including:
• Cardiovascular Medicine
• Infectious... |
|
|
Lessons Learned and New Opportunities: Strategies for Meaningful and Sustainable Improvements to Reduce Health Disparities in Prostate Cancer
This interactive tool is interspersed with videos of leading experts in prostate cancer disparities research. The materials and resources provided in this activity help learners become better able to identify systemic, behavioral, and sociocultural variables that continue to contribute to prostate cancer inequities. The experts in this activity provide insights and resources for learners to help address these disparities not only on patient level, but also within their own institution.
Are ... |
|
|
Apixaban Steps Up to the Plate: The Use of Apixaban for Treatment of Venous Thromboemboli in Patients with Cancer
The incidence of venous thromboemboli (VTE) development in patients with cancer has been reported as much as four to seven-fold higher than that for non-cancer patients. Anticoagulation management remains challenging for these patients, due to the higher risk of recurrent VTE (despite anticoagulant therapy) and bleeding complications, compared to patients without cancer. This application-based continuing pharmacy education activity will provide a 'journal club format' discussion for pharmacist... |
|
|
AHNS 11th International Conference on Head and Neck Cancer
Welcoming Back the World: Striving for Innovation, Quality, Compassion, and Collegiality. The AHNS 2023 scientific program has been thoughtfully designed to bring together all disciplines related to the treatment of head and neck cancer. Our assembled group of renowned head and neck surgeons, radiologists and oncologists have identified key areas of interest and major topics for us to explore.
At the conclusion of the activity, participants will be able to: 1) Assess and apply therapeutic o... |
|
|
Management of Cancer Pain: Current Guidelines
STATEMENT OF NEED
Patients with cancer often suffer from a range of symptoms that negatively impact their quality of life. Among the most significant of these symptoms is pain, which can be caused by surgery, radiation, chemotherapy, targeted therapy, diagnostic procedures, and/or supportive care measures. Between 20% and 50% of patients with cancer experience pain, including moderate-to-severe pain, in approximately 80% of patients with advanced-stage cancer (NCI, 2021). Despite awareness ... |
|
|
Race, Ethnicity, and Breast Cancer: Health Equity Panel Discussion
This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women treated in Cook County.
In this panel discussion and workshop, experts from the University of Chicago Medicine and the University of Illino... |
|
|
OACs and Patients with Malignancies (Part 3 of 3)
Direct acting oral anti-coagulants (DOACs) are a newer class of medications with emerging clinical recommendations and evidence for safe use. Cardiologists and pharmacists have key roles to play as part of the care team to help ensure efficacy and safety of DOACs within the severely ill patient population. |
|
|
Prostate Cancer: The future of PARP inhibitor combination and the evolving paradigm of treatment strategies
Target Audience
Oncologists, physician assistants, nurse practioners, pharmacists and other healthcare professionals involved in the treatment of prostate cancer.
Program Overview
The overall objective for this program is to improve both the knowledge and competence of healthcare professionals who manage patients with prostate cancer using PARP-inhibitor Combination Treatments.
Learning Objectives
Upon completion of this activity, participants should be better able to:
Discus... |
|
|
Hormone Sensitive Prostate Cancer " Therapeutic Approaches
TARGET AUDIENCE:
This activity is designed to meet the educational needs of urologists, medical oncologists, radiation oncologists and other health care professionals responsible for treatment decisions for patients with prostate cancer. Health-care professionals may be unfamiliar with the concept of patient-centered care models that provide optimal outcomes for patients with prostate cancer.
PROGRAM OVERVIEW:
Module 1 covers a review of current recommendations based on NCCN guidelines for ... |
|
|
Treatment of Relapsed/Refractory Ph+ ALL
Target Audience
The target audience for this initiative includes hematology/oncology physicians and other members of the multidisciplinary cancer care team involved in the management of patients with acute lymphocytic leukemia.
Program Overview
This activity is the second in a series of four educational activities focusing on the treatment of relapsed/refractory ALL. Dr. Jessica Leonard, from Oregon Health and Science University, discusses diagnoses and treatment options, and will wal... |
|
|
On the Horizon: HER3-Targeted Antibody-Drug Conjugates for Advanced Solid Tumors An Infographic-Enhanced Journal Club Activity Rationale and Mechanism of Action of HER3-Targeted ADCs for Advanced NSCL
Target Audience
This activity has been designed for oncology clinicians and others who may also have an interest in this topic, specifically those focused on lung and/or breast cancer.
Program Overview
Although treatments for advanced non-small cell lung cancer (NSCLC) and breast cancer are rapidly advancing, these diseases remain incurable. Antibody-drug conjugates (ADCs) offer a novel approach to targeting HER3 as a method of delivering a cytotoxic payload that eliminates tumor cells. T... |
|
|
Where do Anti-TROP2 ADCs Factor into Advanced TNBC Care?
Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series focused on TNBC. This multidisciplinary tumor board discusses a patient with advanced TNBC and how novel anti-TROP2 antibody drug conjugates (ADCs) therapy may play a role. |
|
|
TNBC Case Challenges. Test Your Treatment Skills!
Can you make optimal treatment choices for challenging triple-negative breast cancer (TNBC) cases? Put your TNBC skills to the test in these interactive case challenges. As the third and final activity in the TNBC series, you will navigate through two cases. Education is built into the cases, on practical strategies to meet the treatment needs of diverse patients with TNBC. |
|
|
Early-Stage TNBC: What are the Roles of PARPIs?
Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel of expert faculty will dive into a case involving a patient with early TNBC and discuss the latest data and potential roles of PARP inhibitors (PARPIs) in the first CME activity offered in this TNBC series.
TNBC is an aggressive disease that disproportionately affects African American women in the United States. Treatment opti... |
|
|
Prevention of Medical Errors in Nursing Practice
Medical errors are among the most common health-threatening mistakes that affect patient care. This online activity reviews the categories of medication errors, at-risk patient populations, and best practices in error analysis and reporting.
STATEMENT OF NEED
Medical errors are among the most common health-threatening mistakes that affect patient care, accounting for as many as 250,000 deaths per year in the United States (Makary & Daniel, 2016). Medical errors are considered a global pr... |
|
|
Intensive Review of Internal Medicine - IN PERSON or LIVE STREAMING
The Acclaimed Clinical Update and Board Review
With more than 150 lectures, case discussions, and board preparation sessions, this CME program is one of the most comprehensive reviews of internal medicine offered by the clinical faculty of Harvard Medical School.
It offers accelerated learning:
- For clinicians seeking a practical and comprehensive review that ensures you are up to date across all major fields of internal medicine:
• Newer options for diagnosis: what to choose, w... |
|
|
Treatment Paradigms in Advanced Prostate Cancer: Exploring the Role of PARP Inhibitor Combinations
Target Audience
This activity is designed to meet the educational needs of medical oncologists, urologic oncologists, nurse practitioners, PAs, nurses and other healthcare professionals who manage patients with mCRPC.
Program Overview
A focused online module that examines the mechanistic rationale, discusses the latest evidence, and explores the potential role of PARP inhibitor-based combination therapy in the treatment of patients with advanced prostate cancer.
Learning Objectives... |
|
|
Targeting Large B-Cell Lymphoma: Advances in Treatment
TARGET AUDIENCE:
This activity is designed to meet the educational needs of hematology/oncology physicians, nurse practitioners, nurses, PAs, pharmacists, and other healthcare professionals who care for patients with DLBCL.
PROGRAM OVERVIEW:
The archived version of an interactive nationwide webinar focused on advances in the management of patients with diffuse large B-cell lymphoma (DLBCL).
LEARNING OBJECTIVES:
Upon completion of this activity, participants should be better able to:
-... |
|
|
Medical Crossfire®: Strategies to Manage Transfusional Iron Overload in Patients with ß-hemoglobinopathies: Optimizing Patient Outcomes
Target Audience
This educational activity is directed toward hematologists and hematologist-oncologists, as well as pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with β-hemoglobinopathies.
Program Overview
The β-hemoglobinopathies, sickle-cell disease (SCD) and β-thalassemia, are the most common monogenic disorders worldwide. Despite improved medical supportive therapies, there still is significant long-ter... |
|